Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX) has received an average recommendation of “Moderate Buy” from the fifteen brokerages that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $36.46.

A number of research firms have recently commented on JANX. TD Cowen raised shares of Janux Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Monday, July 20th. Truist Financial reiterated a “buy” rating and issued a $26.00 price objective (down from $80.00) on shares of Janux Therapeutics in a report on Thursday, June 25th. Stifel Nicolaus set a $35.00 price objective on shares of Janux Therapeutics in a research report on Friday, August 7th. Finally, Wolfe Research raised Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 target price on the stock in a research report on Monday, August 24th.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $17.32 on Friday. Janux Therapeutics has a 1-year low of $12.12 and a 1-year high of $35.34. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -10.56 and a beta of 2.40. The business has a 50-day moving average of $17.54 and a 200-day moving average of $15.80.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The business had revenue of $10.27 million during the quarter, compared to analysts’ expectations of $19.07 million. Research analysts expect that Janux Therapeutics will post -1.70 EPS for the current fiscal year.

Institutional Investors Weigh In On Janux Therapeutics

A number of hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC increased its holdings in Janux Therapeutics by 67.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,642 shares of the company’s stock worth $28,000 after purchasing an additional 661 shares during the last quarter. Versant Capital Management Inc grew its position in shares of Janux Therapeutics by 42.8% during the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock worth $40,000 after buying an additional 784 shares in the last quarter. Quantinno Capital Management LP increased its stake in shares of Janux Therapeutics by 7.6% in the first quarter. Quantinno Capital Management LP now owns 26,064 shares of the company’s stock worth $362,000 after buying an additional 1,846 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Janux Therapeutics in the fourth quarter worth $51,000. Finally, Raiffeisen Bank International AG increased its stake in shares of Janux Therapeutics by 9.1% in the second quarter. Raiffeisen Bank International AG now owns 60,000 shares of the company’s stock worth $920,000 after buying an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company based in San Diego, California, developing cancer immunotherapies designed to activate the immune system selectively within the tumor microenvironment. The company’s technology is intended to direct T cells toward cancer cells while limiting activation in healthy tissues.

Janux’s core technology platform, known as TRACTr, uses conditionally activated T-cell engager molecules designed to remain masked in circulation and become activated by proteases that are more prevalent in tumors.